FindTrial
Sign In

The effects of remifentanil on parturient and neonate undergoing caesarean delivery general anaesthesia

The effects of remifentanil on parturient and neonate undergoing caesarean delivery general anaesthesia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800015754
Enrollment
Unknown
Registered
2018-04-18
Start date
2018-04-19
Completion date
Unknown
Last updated
2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

caesarean section

Interventions

two:remifentanil 3.1ng/ml
three:remifentanil 3.2ng/ml
four:remifentanil 3.3ng/ml
one:remifentanil 3.0ng/ml?

Sponsors

Qilu Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Over 36 gestational weeks, absolute or relative contraindications to regional anesthesia: thrombopenia, spine malformation.

Exclusion criteria

Exclusion criteria: Exact fetal distress, severe preeclampsia (SBP higher than 160mmHg or DBP higher than 110mmHg), cardiorespiratory diseases, neurological disease, known congeital abnormalities or signs of fetal compromise, andbody height shorter than 152cm.

Design outcomes

Primary

MeasureTime frame
HR;BP;Apgar scores;epinephrine;noradrenaline;—

Countries

China

Contacts

Public ContactZhang Zhaohang

Qilu Hospital of Shandong University

zzh398@126.com+86 15866718126

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026